Search company, investor...

Predict your next investment

Angel Investor (Individual)



About Amir Motamedi

Headquarters Location

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Amir Motamedi News

Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.

Oct 19, 2020

Authors: Yao Liang Wong, John V Anzola, Robert L Davis, Michelle Yoon, Amir Motamedi, Ashley Kroll, Chanmee P Seo, Judy E Hsia, Sun K Kim, Jennifer W Mitchell, Brian J Mitchell, Arshad Desai, Timothy C Gahman, Andrew K Shiau, Karen Oegema PMID: 25931445 ISSN: 1095-9203 Publication Date: 2015 Jun 05 Abstract Centrioles are ancient organelles that build centrosomes, the major microtubule-organizing centers of animal cells. Extra centrosomes are a common feature of cancer cells. To investigate the importance of centrosomes in the proliferation of normal and cancer cells, we developed centrinone, a reversible inhibitor of Polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole assembly. Centrinone treatment caused centrosome depletion in human and other vertebrate cells. Centrosome loss irreversibly arrested normal cells in a senescence-like G1 state by a p53-dependent mechanism that was independent of DNA damage, stress, Hippo signaling, extended mitotic duration, or segregation errors. In contrast, cancer cell lines with normal or amplified centrosome numbers could proliferate indefinitely after centrosome loss. Upon centrinone washout, each cancer cell line returned to an intrinsic centrosome number “set point.” Thus, cells with cancer-associated mutations fundamentally differ from normal cells in their response to centrosome loss. LinkOut – more resources


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.